• DISCOVERY
    comes
    from
    within.

    Link alterations to the underlying biology of cancer with unparalleled specificity.

  • ACCURACY
    comes
    from
    within.

    Accurate genomic technologies tailored to solve fundamental challenges in oncology.

  • HOPE
    comes
    from
    within.

    Unlocking actionable information to inform treatment decisions.

  • ACCESS
    comes
    from
    within.

    Partnering to make our novel genomic technologies widely available to patients.

  • SOLUTIONS
    come
    from
    within.

    Offering a portfolio of regulated genomic products for laboratories worldwide.

Innovative genomic solutions

to unlock actionable
information from the genome.

Advanced cancer genome analysis to help researchers identify elusive cancer-related genetic changes.

» View our full suite

Obtain the unique genetic information about an individual tumor and make informed treatment decisions.

» Learn about MYPG

Build high-quality in-house with comprehensive NGS testing and analysis of tissue and plasma.

» See Our Diagnostic Solutions

PHARMA-BIOTECH COMPANIES

Advanced cancer genome analysis to help researchers identify elusive cancer-related genetic changes.

PATIENTS & PHYSICIANS

Obtain unique genetic information about individual tumors and make informed treatment decisions.

MOLECULAR LABORATORIES

Build high-quality in-house with comprehensive NGS testing and analysis of tissue and plasma.

recently posted

PGDx Announces Expanded Cancer Testing Contract with U.S. Department of Veteran Affairs

We’re proud to continue our relationship with the VA, which aims to provide our veterans battling cancer with high-quality genomic testing to inform treatment decisions. Learn about our collaboration and our comprehensive, clinically actionable pan-cancer..

latest news & press releases

PGDx Details Design of Small-Panel Mutational Burden Test; Plans IVD Development

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced earlier this month that it is developing a non-invasive next-gen sequencing assay to help identify which cancer patients have the best chance at responding to treatment with immune checkpoint inhibitors.The company received... » View

Personal Genome Diagnostics Awarded National Cancer Institute Contract to Develop Novel Diagnostic for Immuno-Oncology Drugs

—Liquid Biopsy Assay Will Assess Tumor Mutational Load to Identify Those Patients Most Likely to Benefit from Treatment with Checkpoint Inhibitors— BALTIMORE, MD, February 1, 2017 – Personal Genome Diagnostics Inc. (PGDx) today announced that it has been awarded an... » View

Latest Publication

Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

Available on CancerDiscovery

Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance in non-small cell lung cancer patients after initial response to immune checkpoint blockade with anti-PD1 or anti-PD-1/anti-CTLA4 antibodies.

Industry News

New genomic analysis technology has been used to demonstrate how cancer drug resistance evolves

Available on SelectScience

Mark Sausen, PGDx Vice President of Research & Development, commented, "Despite the increased efficacy and durability of treatment seen with IO therapies, some patients develop resistance to the therapy, and this study for the first time elucidates how this may result from the evolving cancer genome landscape..."

latest news & press releases

PGDx Details Design of Small-Panel Mutational Burden Test; Plans IVD Development

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced earlier this month that it is developing a non-invasive next-gen sequencing assay to help identify which cancer patients have the best chance at responding to treatment with immune checkpoint inhibitors.The company received... » View

Personal Genome Diagnostics Awarded National Cancer Institute Contract to Develop Novel Diagnostic for Immuno-Oncology Drugs

—Liquid Biopsy Assay Will Assess Tumor Mutational Load to Identify Those Patients Most Likely to Benefit from Treatment with Checkpoint Inhibitors— BALTIMORE, MD, February 1, 2017 – Personal Genome Diagnostics Inc. (PGDx) today announced that it has been awarded an... » View